Aim: The objective of this study was to investigate a possible correlation between the plasminogen activator inhibitor-1 (PAI-1) and methylene tetrahydrofolate reductase (MTHFR) polymorphisms and unexplained spontaneous miscarriages (SM). Materials and Methods: PAI-1 polymorphisms were evaluated in 150 women with pregnancy in their history. One hundred women with a history of SM formed the study group and 50 women with normal pregnancies served as the control group. Also, the combination of PAI-1 and MTHFR polymorphisms were evaluated in 138 women out of a total of 150, which included 92 women with SM in their history compared to 46 women in the control group. For statistical analysis, χ2 test, Phi, and Cramer V tests were used; p < 0.05 was taken as a statistically significant result. Results: Our findings show: (a) the correlation between SM and PAI-1 mutations reaches statistical significance (p = 0.026); (b) there was a statistically significant difference between heterozygous PAI-1 in women with only 1 SM compared to the control group (p = 0.047); (c) the comparison of combinations of both mutations, PAI-1 and MTHFR, with the control group demonstrates statistical significance in favor of women with SM and both mutations (p = 0.022). Conclusion: PAI-1 and MTHFR polymorphisms may play an important role in pregnancy complications because heterozygous PAI-1 mutations and a combination of both PAI-1 and MTHFR mutations might contribute to SM.

Kuvačić I, Kurjak A, Đelmiš J (eds): Obstetrics. Zagreb, Medicinska Naklada, 2009.
Bonde JPE, Jørgensen KT, Bonzini M, Palmer KT: Risk of miscarriage and occupational activity: a systematic review and meta-analysis regarding shift work, working hours, lifting, standing and physical workload. Scand J Work Environ Health 2013;39:325-334.
Coulam CB, Clark DA, Beer AE: Current clinical options for diagnosis and treatment of recurrent spontaneous abortion. Am J Reprod Immunol 1997;38:57-74.
Stephenson MD: Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril 1996;66:24-29.
Pandey S, Pandey A, Chauhan UK, Tripathi A, Tripathi J, Dubey S, Deo Saket R: Recurrent pregnancy loss and association of MTHFR, PAI-1 and ACE gene polymorphisms in women. Int J Clin Biomed Res 2015;1:50-55.
Li TC, Makris M, Tomsu M, Tuckerman E, Laird S: Recurrent miscarriage: aetiology, management and prognosis. Hum Reprod Update 2002;8:463-481.
Toth B, Vocke F, Rogenhofer N, Friese K, Thaler CJ, Lohse P: Paternal thrombophilic gene mutations are not associated with recurrent miscarriage. Am J Reprod Immunol 2008;60:325-332.
Zorio E, Gilabert-Estellés J, España F, Ramón LA, Cosín R, Estellés A: Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 2008;15:923-929.
Đorđević V, Gvozdenov M, Pruner I, Tomić B, Kovac M, Antonijević N, Radojković D: The prevalence of PAI-1 4G/5G gene variant in Serbian population. Med Glasnik 2013;18:28-41.
Yamada N, Arinami T, Yamakawa-Kobayashi K, Watanabe H, Sohda S, Hamada H, Kubo T, Hamaguchi H: The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia. J Hum Genet 2000;45:138-141.
Madách K, Aladzsity I, Szilágyi A, Fust G, Gal J, Pénzes I, Prohaszka Z: 4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study. Crit Care 2010;14:79.
Eriksson P, Kallin B, van't Hooft FM, Båvenholm P, Hamsten A: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851-1855.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuve LP, Rozen R: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.
McNulty H, McKinley MC, Wilson B, McPartlin J, Strain JJ, Weir DG, Scott JM: Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements. Am J Clin Nutr 2002;76:436-441.
Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ: Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995;56:142-150.
Chen H, Nie S, Lu M: Association between plasminogen activator inhibitor-1 gene polymorphisms and recurrent pregnancy loss: a systematic review and meta-analysis. Am J Reprod Immunol 2015;73:292-300.
Xuejiao L, Yukun L, Rui Z, Jianping T, Libin C, Yinglin L: Meta-analysis of the association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss. Med Sci Monit 2015;21:1051-1056.
Glueck CJ, Phillips H, Cameron D, Wang P, Fontaine RN, Moore SK, Sieve-Smith L, Tracy T: The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism 2000;49:845-852.
Wolf CE, Haubelt H, Pauer HU, Hinney B, Krome-Cesar C, Legler TJ, Hellstem P, Emons G, Zoll B, Köhler M: Recurrent pregnancy loss and its relation to FV Leiden, FII G20210A and polymorphisms of plasminogen activator and plasminogen activator inhibitor. Pathophysiol Haemost Thromb 2003;33:134-137.
Sun L, Lv H, Wei W, Zhang D, Guan Y: Angiotensin-convertingenzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome. J Endocrinol Invest 2009;33:77-82.
Kim NK, Choi YK, Kang MS, Choi DH, Cha SH, An MO, Lee S, Jeung M, Ko JJ, Oh D: Influence of combined methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase enhancer region (TSER) polymorphisms to plasma homocysteine levels in Korean patients with recurrent spontaneous abortion. Thromb Res 2006;117:653-658.
Biswas A, Choudhry P, Mittal A, Meena A, Ranjan R, Choudhry VP, Saxena R: Recurrent abortions in Asian Indians: no role of factor V Leiden Hong Kong/Cambridge mutation and MTHFR polymorphism. Clin Appl Thromb Hemost 2008;14:102-104.
Hotoleanu C, Chouky E: Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in a patient with coronary artery disease and repetitive miscarriages. Rom J Intern Med 2012;50:313-316.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.